The state of the art on treatment of Crohn's disease

Area of Science:

• Gastroenterology and immunology

Background:

• Crohn's disease (CD) is a chronic gastrointestinal disorder with stable incidence in Western countries but rising rates in Asia.
• Immunomodulators and biologics are key treatments to prevent long-term bowel damage and disability in Crohn's disease.
• Therapeutic drug monitoring optimizes thiopurine and anti-TNF therapies, while new biologics and biosimilars offer evolving treatment options.

Purpose of the Study:

• To review the literature on the efficacy, safety, and withdrawal of current and emerging therapies for Crohn's disease.
• To examine the evolution of therapeutic targets in Crohn's disease management.
• To highlight the role of biosimilars in addressing the cost and accessibility of biologic treatments for Crohn's disease.

Main Methods:

• Literature review of scientific articles and clinical studies on Crohn's disease treatments.
• Analysis of data on drug efficacy, safety profiles, and patient withdrawal rates.
• Examination of trends in the development of new biologic agents and biosimilars for Crohn's disease.

Main Results:

• Immunomodulators and biologics are crucial for managing Crohn's disease, reducing complications and improving patient outcomes.
• Therapeutic drug monitoring enhances the effectiveness of thiopurines and anti-TNF agents.
• The development of novel biologics and the increasing availability of biosimilars are expanding treatment options and potentially reducing costs for Crohn's disease.

Conclusions:

• Current and emerging therapies, including biologics and biosimilars, are vital for managing Crohn's disease progression and improving patient quality of life.
• Continued research into novel therapeutic targets and personalized treatment strategies is essential for optimizing Crohn's disease care.
• Biosimilars represent a significant advancement in making advanced biologic therapies more accessible for Crohn's disease patients globally.